Kong-Ju Lee

Title: Innovations of Kong-Ju Lee in Chemokine Research

Introduction

Kong-Ju Lee is a notable inventor based in Kyounggi-do, South Korea. He has made significant contributions to the field of biochemistry, particularly in the development of variants of chemokines. His work focuses on enhancing biological activity for potential therapeutic applications.

Latest Patents

Kong-Ju Lee holds a patent for a variant of C6 β-chemokine leukotactin-1, known as shLkn-1. This invention relates to a truncated form of Lkn-1, which has enhanced biological activity. The recombinant shLkn-1 is generated by omitting 26 amino acid residues from the amino terminus of Lkn-1, resulting in a protein that contains 66 amino acids. This innovative protein has shown the ability to inhibit colony formation and cell proliferation in vivo, indicating its potential as a drug for antibody production, treatment during HIV-1 infection, protection of bone marrow stem cells during chemotherapy or radiotherapy, and inhibition of leukemia.

Career Highlights

Throughout his career, Kong-Ju Lee has focused on the intersection of biochemistry and therapeutic applications. His research has led to advancements in understanding chemokine functions and their potential uses in medicine. His patent reflects his commitment to developing solutions for serious health issues.

Collaborations

Kong-Ju Lee has collaborated with notable colleagues in his field, including Soo-Il Chung and Doo-Hong Park. These collaborations have likely contributed to the depth and impact of his research.

Conclusion

Kong-Ju Lee's innovative work in the field of chemokines exemplifies the potential of scientific research to lead to significant medical advancements. His patent for shLkn-1 highlights the importance of continued innovation in biochemistry.